The FDA has granted its fast-track designation to an experimental vaccine for Staphylococcus aureus.
The multivalent toxoid vaccine made by LimmaTech Biologics, a Switzerland-based drug company, is designed to prevent skin and soft tissue infections caused by the bacterial pathogen. There are currently no FDA-approved vaccines for Staph aureus infections, according to a Dec. 19 news release.
By gaining the agency's fast-track authorization, LimmaTech can discuss the clinical development plan for the vaccine, LBT-SA7, with the FDA more frequently than normal.